Cyclic peptides containing tryptophan and arginine as Src kinase inhibitors

Amir Nasrolahi Shirazi, Rakesh Kumar Tiwari, Alex Brown, Dindyal Mandal, Gongqin Sun, Keykavous Parang

Research output: Contribution to journalArticle

Abstract

A number of cyclic and linear peptides containing various combinations of amino acids were evaluated for their Src kinase inhibitory potency. Among all the peptides, cyclic decapeptide C[RW]5 containing alternative arginine (R) and tryptophan (W) residues was found to be the most potent Src kinase inhibitor. C[RW]5 showed higher inhibitory activity (IC 50 = 2.8 μM) than C[KW]5, L(KW)5, C[RW] 4, and C[RW]3 with IC50 values of 46.9, 69.1, 21.5, and 25.0 μM, respectively, as determined in a fluorescence intensity-based assay. Thus, the cyclic nature, the presence of arginine, ring size, and the number of amino acids in the structure of the peptide were found to be critical in Src kinase inhibitory potency. The IC50 value of C[RW]5 was found to be 0.8 μM in a radioactive assay using [γ-32P]-ATP and polyE4Y as the substrate. C[RW] 5 was a noncompetitive Src kinase inhibitor, showing approximately fourfold more selectivity towards Src than Abl.

Original languageEnglish (US)
Pages (from-to)3230-3234
Number of pages5
JournalBioorganic and Medicinal Chemistry Letters
Volume23
Issue number11
DOIs
StatePublished - Jun 1 2013
Externally publishedYes

Fingerprint

Cyclic Peptides
src-Family Kinases
Tryptophan
Arginine
Inhibitory Concentration 50
Assays
Amino Acids
Peptides
Adenosine Triphosphate
Fluorescence
Substrates

Keywords

  • Arginine
  • Cyclic peptides
  • Src
  • Tryptophan
  • Tyrosine kinase

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Drug Discovery
  • Organic Chemistry
  • Molecular Medicine
  • Molecular Biology
  • Clinical Biochemistry
  • Biochemistry

Cite this

Nasrolahi Shirazi, A., Tiwari, R. K., Brown, A., Mandal, D., Sun, G., & Parang, K. (2013). Cyclic peptides containing tryptophan and arginine as Src kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 23(11), 3230-3234. https://doi.org/10.1016/j.bmcl.2013.03.124

Cyclic peptides containing tryptophan and arginine as Src kinase inhibitors. / Nasrolahi Shirazi, Amir; Tiwari, Rakesh Kumar; Brown, Alex; Mandal, Dindyal; Sun, Gongqin; Parang, Keykavous.

In: Bioorganic and Medicinal Chemistry Letters, Vol. 23, No. 11, 01.06.2013, p. 3230-3234.

Research output: Contribution to journalArticle

Nasrolahi Shirazi, A, Tiwari, RK, Brown, A, Mandal, D, Sun, G & Parang, K 2013, 'Cyclic peptides containing tryptophan and arginine as Src kinase inhibitors', Bioorganic and Medicinal Chemistry Letters, vol. 23, no. 11, pp. 3230-3234. https://doi.org/10.1016/j.bmcl.2013.03.124
Nasrolahi Shirazi, Amir ; Tiwari, Rakesh Kumar ; Brown, Alex ; Mandal, Dindyal ; Sun, Gongqin ; Parang, Keykavous. / Cyclic peptides containing tryptophan and arginine as Src kinase inhibitors. In: Bioorganic and Medicinal Chemistry Letters. 2013 ; Vol. 23, No. 11. pp. 3230-3234.
@article{403257d8d35b48a28e228d64f1ea0e6d,
title = "Cyclic peptides containing tryptophan and arginine as Src kinase inhibitors",
abstract = "A number of cyclic and linear peptides containing various combinations of amino acids were evaluated for their Src kinase inhibitory potency. Among all the peptides, cyclic decapeptide C[RW]5 containing alternative arginine (R) and tryptophan (W) residues was found to be the most potent Src kinase inhibitor. C[RW]5 showed higher inhibitory activity (IC 50 = 2.8 μM) than C[KW]5, L(KW)5, C[RW] 4, and C[RW]3 with IC50 values of 46.9, 69.1, 21.5, and 25.0 μM, respectively, as determined in a fluorescence intensity-based assay. Thus, the cyclic nature, the presence of arginine, ring size, and the number of amino acids in the structure of the peptide were found to be critical in Src kinase inhibitory potency. The IC50 value of C[RW]5 was found to be 0.8 μM in a radioactive assay using [γ-32P]-ATP and polyE4Y as the substrate. C[RW] 5 was a noncompetitive Src kinase inhibitor, showing approximately fourfold more selectivity towards Src than Abl.",
keywords = "Arginine, Cyclic peptides, Src, Tryptophan, Tyrosine kinase",
author = "{Nasrolahi Shirazi}, Amir and Tiwari, {Rakesh Kumar} and Alex Brown and Dindyal Mandal and Gongqin Sun and Keykavous Parang",
year = "2013",
month = "6",
day = "1",
doi = "10.1016/j.bmcl.2013.03.124",
language = "English (US)",
volume = "23",
pages = "3230--3234",
journal = "Bioorganic and Medicinal Chemistry Letters",
issn = "0960-894X",
publisher = "Elsevier Limited",
number = "11",

}

TY - JOUR

T1 - Cyclic peptides containing tryptophan and arginine as Src kinase inhibitors

AU - Nasrolahi Shirazi, Amir

AU - Tiwari, Rakesh Kumar

AU - Brown, Alex

AU - Mandal, Dindyal

AU - Sun, Gongqin

AU - Parang, Keykavous

PY - 2013/6/1

Y1 - 2013/6/1

N2 - A number of cyclic and linear peptides containing various combinations of amino acids were evaluated for their Src kinase inhibitory potency. Among all the peptides, cyclic decapeptide C[RW]5 containing alternative arginine (R) and tryptophan (W) residues was found to be the most potent Src kinase inhibitor. C[RW]5 showed higher inhibitory activity (IC 50 = 2.8 μM) than C[KW]5, L(KW)5, C[RW] 4, and C[RW]3 with IC50 values of 46.9, 69.1, 21.5, and 25.0 μM, respectively, as determined in a fluorescence intensity-based assay. Thus, the cyclic nature, the presence of arginine, ring size, and the number of amino acids in the structure of the peptide were found to be critical in Src kinase inhibitory potency. The IC50 value of C[RW]5 was found to be 0.8 μM in a radioactive assay using [γ-32P]-ATP and polyE4Y as the substrate. C[RW] 5 was a noncompetitive Src kinase inhibitor, showing approximately fourfold more selectivity towards Src than Abl.

AB - A number of cyclic and linear peptides containing various combinations of amino acids were evaluated for their Src kinase inhibitory potency. Among all the peptides, cyclic decapeptide C[RW]5 containing alternative arginine (R) and tryptophan (W) residues was found to be the most potent Src kinase inhibitor. C[RW]5 showed higher inhibitory activity (IC 50 = 2.8 μM) than C[KW]5, L(KW)5, C[RW] 4, and C[RW]3 with IC50 values of 46.9, 69.1, 21.5, and 25.0 μM, respectively, as determined in a fluorescence intensity-based assay. Thus, the cyclic nature, the presence of arginine, ring size, and the number of amino acids in the structure of the peptide were found to be critical in Src kinase inhibitory potency. The IC50 value of C[RW]5 was found to be 0.8 μM in a radioactive assay using [γ-32P]-ATP and polyE4Y as the substrate. C[RW] 5 was a noncompetitive Src kinase inhibitor, showing approximately fourfold more selectivity towards Src than Abl.

KW - Arginine

KW - Cyclic peptides

KW - Src

KW - Tryptophan

KW - Tyrosine kinase

UR - http://www.scopus.com/inward/record.url?scp=84877584228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877584228&partnerID=8YFLogxK

U2 - 10.1016/j.bmcl.2013.03.124

DO - 10.1016/j.bmcl.2013.03.124

M3 - Article

VL - 23

SP - 3230

EP - 3234

JO - Bioorganic and Medicinal Chemistry Letters

JF - Bioorganic and Medicinal Chemistry Letters

SN - 0960-894X

IS - 11

ER -